Wealthquest Corp Buys 115 Shares of Johnson & Johnson (NYSE:JNJ)

Wealthquest Corp boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,277 shares of the company’s stock after acquiring an additional 115 shares during the period. Wealthquest Corp’s holdings in Johnson & Johnson were worth $1,342,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in JNJ. IFS Advisors LLC increased its stake in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter valued at $31,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter valued at $35,000. Mowery & Schoenfeld Wealth Management LLC increased its stake in shares of Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after purchasing an additional 91 shares during the last quarter. Finally, Activest Wealth Management bought a new position in shares of Johnson & Johnson in the 3rd quarter valued at $40,000. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Down 1.9 %

Shares of NYSE:JNJ opened at $145.39 on Thursday. The company has a market capitalization of $350.04 billion, a price-to-earnings ratio of 21.04, a P/E/G ratio of 2.50 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business’s 50-day moving average is $148.26 and its 200-day moving average is $156.12. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.29 EPS. Equities research analysts predict that Johnson & Johnson will post 9.95 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on JNJ. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 17th. Royal Bank of Canada boosted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Finally, Bank of America reduced their price objective on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a research report on Friday, January 17th. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $173.27.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.